Global Bovine Blood Plasma Derivatives Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Derivative Type;

Immunoglobulin, Fibrinogen, Serum Albumin, Fetal Bovine Serum, Thrombin, Transferrin, New Born Calf Serum, and Others

By Application;

Pharmaceutical Industry, Diagnostic Industry, Cell Culture/ Biotechnology, Research & Development, Food Industry, Cosmetic Industry, and Others

By End User;

Hospitals, Research Laboratories, Food Processing Companies, Veterinary Clinics, and Others

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa, and Latin America - Report Timeline (2021 - 2031)
Report ID: Rn772417729 Published Date: May, 2025 Updated Date: June, 2025

Bovine Blood Plasma Derivatives Market Overview

Bovine Blood Plasma Derivatives Market (USD Million)

Bovine Blood Plasma Derivatives Market was valued at USD 3,945.50 million in the year 2024. The size of this market is expected to increase to USD 5,893.50 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.9%.


Global Bovine Blood Plasma Derivatives Market Growth, Share, Size, Trends and Forecast

*Market size in USD million

CAGR 5.9 %


Study Period2025 - 2031
Base Year2024
CAGR (%)5.9 %
Market Size (2024)USD 3,945.50 Million
Market Size (2031)USD 5,893.50 Million
Market ConcentrationMedium
Report Pages396
3,945.50
2024
5,893.50
2031

Major Players

  • Sigma-Aldrich Corporation
  • Proliant Biologicals
  • LAMPIRE Biological Laboratories, Inc
  • Lake Immunogenics Inc
  • Merck KGaA
  • Thermo Fisher Scientific Inc
  • Kraeber & Co GmbH
  • Rocky Mountain Biologicals Inc
  • Bovogen Biologicals Pty Ltd
  • Auckland BioSciences Ltd

Market Concentration

Consolidated - Market dominated by 1 - 5 major players

Global Bovine Blood Plasma Derivatives Market

Fragmented - Highly competitive market without dominant players


The Bovine Blood Plasma Derivatives Market is experiencing sustained growth due to its rising use in biomedical and pharmaceutical applications. Known for their rich bioactive and protein content, these derivatives are essential in drug development, vaccine production, and cell culture processes. Over 40% of manufacturing entities now include bovine plasma derivatives in various formulations to enhance product performance and biological compatibility.

Enhancing Animal Health and Feed Efficiency
Bovine plasma derivatives are gaining traction in animal health and nutrition as functional feed components. These ingredients are especially beneficial in improving immunity and growth rates among livestock. Approximately 35% of animal nutrition products incorporate plasma-derived proteins, reinforcing their growing importance in commercial feed formulations focused on animal wellness and productivity.

Innovations in Plasma Processing Techniques
Advanced processing technologies are enhancing the usability of bovine plasma, improving both safety and performance. Innovations in fractionation, sterilization, and drying methods have increased the reliability of these derivatives. More than 45% of industry producers are adopting these technologies to ensure consistent, high-quality derivatives suitable for pharmaceutical and therapeutic applications.

Supportive Research and Regulatory Landscape
Growing research initiatives and regulatory support are catalyzing further development in the bovine plasma space. With over 38% of funding in biomedical research directed toward plasma-derived materials, regulatory bodies and institutions are facilitating innovation. This backing is expected to broaden the market’s application potential in healthcare and allied fields.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Derivative Type
    2. Market Snapshot, By Application
    3. Market Snapshot, By End User
    4. Market Snapshot, By Region
  4. Bovine Blood Plasma Derivatives Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Increasing Demand for Blood Plasma Derivatives
        2. Rising Prevalence of Chronic Diseases
        3. Technological Advancements in Blood Plasma Fractionation
        4. Expanding Applications in Veterinary Medicine
      2. Restraints
        1. Strict regulations on animal-derived products

        2. Concerns over disease transmission risks

        3. High processing and purification costs

        4. Limited awareness in emerging markets

      3. Opportunities
        1. Emerging Markets in Asia-Pacific and Latin America
        2. Research and Development Initiatives
        3. Strategic Collaborations and Partnerships
        4. Focus on Product Diversification
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Bovine Blood Plasma Derivatives Market, By Derivative Type, 2021 - 2031 (USD Million)
      1. Immunoglobulin
      2. Fibrinogen
      3. Serum Albumin
      4. Fetal Bovine Serum
      5. Thrombin
      6. Transferrin
      7. New Born Calf Serum
      8. Others
    2. Bovine Blood Plasma Derivatives Market, By Application, 2021 - 2031 (USD Million)
      1. Pharmaceutical Industry
      2. Diagnostic Industry
      3. Cell Culture/ Biotechnology
      4. Research and Development
      5. Food Industry
      6. Cosmetic Industry
      7. Others
    3. Bovine Blood Plasma Derivatives Market, By End User, 2021 - 2031 (USD Million)
      1. Hospitals
      2. Research Laboratories
      3. Food Processing Companies
      4. Veterinary Clinics
      5. Others
    4. Bovine Blood Plasma Derivatives Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Sigma-Aldrich Corporation
      2. Proliant Biologicals
      3. LAMPIRE Biological Laboratories, Inc
      4. Lake Immunogenics Inc
      5. Merck KGaA
      6. Thermo Fisher Scientific Inc
      7. Kraeber & Co GmbH
      8. Rocky Mountain Biologicals Inc
      9. Bovogen Biologicals Pty Ltd
      10. Auckland BioSciences Ltd
  7. Analyst Views
  8. Future Outlook of the Market